Understanding how DNA changes contribute to cancer development
Molecular basis for aberrant de novo DNA methylation in cancer
This study is looking at how changes in DNA, specifically in areas that help control important genes, might lead to cancer, and it hopes to find new ways to treat patients by understanding these changes better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11014330 on NIH RePORTER |
What this research studies
This research investigates the role of DNA methylation, a crucial process that regulates gene activity, in the development of cancer. It focuses on how abnormal patterns of DNA methylation occur, particularly in regions known as CpG islands, which are important for the function of tumor suppressor genes. By studying the enzymes responsible for establishing these methylation patterns, the research aims to uncover the underlying mechanisms that lead to cancer initiation. Patients may benefit from insights that could lead to new therapeutic strategies targeting these methylation changes.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with various types of cancer, particularly those with known aberrant DNA methylation patterns.
Not a fit: Patients with cancers that do not exhibit DNA methylation abnormalities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments that restore normal gene function in cancer patients.
How similar studies have performed: Previous research has shown promising results in targeting DNA methylation in cancer, indicating that this approach has potential for success.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Armache, Karim Jean — New York University School of Medicine
- Study coordinator: Armache, Karim Jean
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.